×

MorphoSys to Host Q1 2015 Conference Call on 05 May 2015

Martinsried / Munich, Germany, April 29, 2015 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first three months' 2015 results on 05 May 2015 at 7:00 am CEST.

At 2:00 pm CEST (1:00 pm BST, 8:00 am EDT), the Management Board of MorphoSys AG will host a public conference call to present MorphoSys's financial results for the first three months of 2015 and provide further details on the Company's latest developments.

Dial-in numbers (listen only):

Germany: + 49 89 2444 32975

United Kingdom: + 44 20 3003 2666

USA: +1 202 204 1514

A replay of the conference call and manuscripts of the conference including questions and answers will be available on www.morphosys.com/conference-calls in due course.

The Annual General Meeting of MorphoSys AG will take place on 08 May 2015 in Munich. A live-webcast of the event and all related information are available on www.morphosys.com/agm.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Manager Corporate Communications & IR

Jessica Rush
Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Conference Call Alert Q1 2015 http://hugin.info/130295/R/1916485/685300.pdf

HUG#1916485

Source:MorphoSys AG